


FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE



ATTY DOCKET NO.
TSRI 897.1

SERIAL NO.
10/527,525

APPLICANT
Markou, et al.

FILING DATE
10/14/2005

GROUP
1617

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	1	Waterhouse, et al., <u>Society for Neuroscience Abstracts</u> 27, No. 2: 2358 (2001)
	2	Ahmed, et al., "Neurobiological Evidence for Hedonic Allostasis Associated with Escalating Cocaine Use", <u>Nature Neuroscience</u> 5, No. 7: 625-626 (2002)
	3	Harrison, et al., "Fluoxetine Combined with a Serotonin-1A Receptor Antagonist Reversed Reward Deficits Observed during Nicotine and Amphetamine Withdrawal in Rats", <u>Neuropsychopharmacology</u> 25, No. 1: 55-71 (2001)
	4	Harrison, et al., "Nicotine Potentiation of Brain Stimulation Reward Reversed by DHβE and SCH 23390, but not by Eticlopride, LY 314582 or MPEP in Rats", <u>Psychopharmacology</u> 160: 56-66 (2002)
	5	Cryan, et al., "Bupropion Enhances Brain Reward Function and Reverses the Affective and Somatic Aspects of Nicotine Withdrawal in the Rat", <u>Psychopharmacology</u> 168: 347-358 (2003)
	6	Shigemoto, et al., "Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus", <u>The Journal of Neuroscience</u> 17, No. 19: 7503-7522 (1997)
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.